JoAl Mayor

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Nancy U. Lin, Virginia F. Borges, Carey K. Anders et al. · Journal of Clinical Oncology · 2020 · 521 citations · Full text

Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects

Ariel R. Topletz‐Erickson, Anthony Lee, JoAl Mayor et al. · The Journal of Clinical Pharmacology · 2020 · 29 citations · Full text

The effective use of plerixafor as a real‐time rescue strategy for patients poorly mobilizing autologous CD34⁺ cells

Ajay K. Gopal, Mehdi Karami, JoAl Mayor et al. · Journal of Clinical Apheresis · 2012 · 27 citations · Full text

MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress.

John H. Strickler, Yoshiaki Nakamura, Takayuki Yoshino et al. · Journal of Clinical Oncology · 2021 · 21 citations

Breast Oncology, Oncology, Her2 Expression +15

MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in progress.

Daniel V.T. Catenacci, John H. Strickler, Yoshiaki Nakamura et al. · Journal of Clinical Oncology · 2022 · 15 citations · Full text

Breast Oncology, Esophageal Cancer, Gastroenterology +18